JP2022548095A5 - - Google Patents
Info
- Publication number
- JP2022548095A5 JP2022548095A5 JP2022516379A JP2022516379A JP2022548095A5 JP 2022548095 A5 JP2022548095 A5 JP 2022548095A5 JP 2022516379 A JP2022516379 A JP 2022516379A JP 2022516379 A JP2022516379 A JP 2022516379A JP 2022548095 A5 JP2022548095 A5 JP 2022548095A5
- Authority
- JP
- Japan
- Prior art keywords
- carbocyryl
- heteroatoms selected
- alkyl
- membered
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901229P | 2019-09-16 | 2019-09-16 | |
| US62/901,229 | 2019-09-16 | ||
| PCT/IB2020/058641 WO2021053555A1 (en) | 2019-09-16 | 2020-09-16 | Glue degraders and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548095A JP2022548095A (ja) | 2022-11-16 |
| JP2022548095A5 true JP2022548095A5 (https=) | 2023-09-21 |
Family
ID=72717893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516379A Pending JP2022548095A (ja) | 2019-09-16 | 2020-09-16 | 接着分解剤及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220363671A1 (https=) |
| EP (1) | EP4031243A1 (https=) |
| JP (1) | JP2022548095A (https=) |
| CN (1) | CN114401960A (https=) |
| WO (1) | WO2021053555A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| IL303458A (en) * | 2020-12-09 | 2023-08-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| US20240085421A1 (en) | 2021-01-13 | 2024-03-14 | Monte Rosa Therapeutics, Inc. | Methods for the identification of degrons |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| WO2022256623A1 (en) | 2021-06-04 | 2022-12-08 | Monte Rosa Therapeutics, Inc. | E3 ligase fusion proteins for proximity detection |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| WO2023091567A1 (en) | 2021-11-17 | 2023-05-25 | Monte Rosa Therapeutics, Inc. | Degron and neosubstrate identification |
| CN114487379A (zh) * | 2022-01-17 | 2022-05-13 | 东南大学 | 一种用于联合检测ca125与he4的试纸条 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| CN114410607A (zh) * | 2022-03-22 | 2022-04-29 | 上海威高医疗技术发展有限公司 | 嗜热羧酸酯酶突变体及其应用 |
| CN116789637B (zh) * | 2022-05-13 | 2024-08-02 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2024073871A1 (en) * | 2022-10-04 | 2024-04-11 | Biofront Ltd | Gspt1 degraders, compositions comprising the degrader, and methods of using the same |
| CN121311479A (zh) | 2023-01-09 | 2026-01-09 | 蒙特罗萨治疗股份公司 | Vav1的靶向降解 |
| PE20260307A1 (es) | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
| AU2024298923A1 (en) | 2023-07-25 | 2026-01-22 | Monte Rosa Therapeutics Ag | Substituted piperidinediones for targeted protein degradation |
| WO2025232887A1 (en) * | 2024-05-10 | 2025-11-13 | Shanghai Degron Biomedical Technology Co., Ltd. | Wee1 degraders and uses thereof |
| WO2026013577A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1 |
| WO2026013576A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Dihydrouracil derivatives useful for the targeted degradation of vav1 |
| WO2026013578A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Combinations comprising vav1-targeting degraders |
| WO2026067646A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海美悦生物科技发展有限公司 | 联苯类化合物、及其药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
| AR077004A1 (es) * | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| BR112018068906A2 (pt) * | 2016-03-16 | 2019-01-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019140387A1 (en) * | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN120698983A (zh) * | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
-
2020
- 2020-09-16 WO PCT/IB2020/058641 patent/WO2021053555A1/en not_active Ceased
- 2020-09-16 EP EP20785841.6A patent/EP4031243A1/en active Pending
- 2020-09-16 CN CN202080063698.5A patent/CN114401960A/zh active Pending
- 2020-09-16 US US17/642,292 patent/US20220363671A1/en active Pending
- 2020-09-16 JP JP2022516379A patent/JP2022548095A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548095A5 (https=) | ||
| TWI765448B (zh) | Kras g12c抑制劑 | |
| JP2025508703A5 (https=) | ||
| JP6863970B2 (ja) | ヘテロ環式化合物およびそれらの使用 | |
| JP2024534187A5 (https=) | ||
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| KR102346508B1 (ko) | 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물 | |
| JP2022505835A5 (https=) | ||
| JP2021501786A (ja) | 統合的ストレス経路の調節剤 | |
| CN112154142A (zh) | 整合应激通路的调节剂 | |
| JP2021501788A (ja) | 統合的ストレス経路の調節剤 | |
| JP2021501790A (ja) | 統合的ストレス経路の調節剤 | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| WO2018092089A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2021501787A (ja) | 統合的ストレス経路の調節剤 | |
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2008523041A5 (https=) | ||
| JP2021501781A (ja) | 統合的ストレス経路の調節剤 | |
| AU2011268906A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| JP2007534687A5 (https=) | ||
| MX2010001677A (es) | Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| EA010393B1 (ru) | Производные хинолинона | |
| JP2016515098A5 (https=) | ||
| JP2005509038A5 (https=) |